Answers are grounded in this paper and cite their sources.
Prolactin-secreting adenomas (prolactinomas) are the most common secreting pituitary neuroendocrine tumors (PitNETs\2017) (27.2%-40%) Invasive giant prolactinomas (IGPs) are a rare subtype of PitNETs (0.5%-4.4%). Their criteria include a maximum tumor diameter >40 mm, serum prolactin concentration >200 ng/mL, and tumor invasion into the cavernous sinus. IGPs are more common in young men due to its late diagnosis.1 Biochemical and instrumental control of tumor growth is a current problem in neuroendocrinology due to its aggressive clinical course.2 Dopamine agonists (DA) are used in the first-line treatment of prolactinomas.3 However, their effectiveness in the treatment of IGPs is discussed.4 The successful treatment by AD cabergoline of IGP, incidentally detected on MRI after a car accident of a man aged 38 years, is presented. MRI was showed: The sella turcica is dilated, there is an invasion of bulky mass (measuring 26 × 24 × 25 mm) into sinus cavernous, which is tightly adjacents to the right internal carotid artery with deviation of the pituitary infundibulum to the left and back. After treatment of the injury, further blood examination was prescribed. Laboratory data showed the following results: serum PRL 1415.94 ng/mL (ref. 2.64-13.13), big-big PRL <1%, TSH 1.614 μIU/mL (0.4-4.85), morning cortisol 8.49 μg/dl (4.82-19.5), somatomedine C1 (IGF-1) 121 ng/mL (58-219), LH 2.04 mIU/mL (0.57-12.07), FSH 2.18 mIU/mL (0.95-11.95), testosterone total 12.39 nmol/l (8.33-30.19). It was prescribed cabergoline (dosage 0.5 mg per week). After 1 months from the start of medical treatment PRL concentration decreased to 2.67 ng/mL, and after 4 months – down to 1.53 ng/mL, tumor volume decreased by 19.74%, LH level increased up to 3.68 mIU/mL, FSH level – to 3.93 mIU/mL, testosterone total concentration – to 17.05 nmol/l. Conclusion: Thus, the results of drug treatment showed a very good tumor sensitivity to cabergoline without side effects with an improvement of pituitary gonadotropic function, which predetermines further positive dynamics of tumor size reduction.
No takes yet. Share an insight, caveat, or question.
Mykhailo Kyryliuk (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: